Active	Status	Sponsor type	Region	Phase	Filter
10 Active 12 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vitolo, Umberto
FIL FLAZ12, NCT01827605 / 2012-000251-14: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)	Active, not recruiting	3	159	Europe	ZEVALIN, RIT, BEAM, ASCT	Fondazione Italiana Linfomi - ETS	Relapsed Follicular Lymphoma	10/19	01/24
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients	Active, not recruiting	3	128	Europe	R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)	Fondazione Italiana Linfomi - ETS	Lymphoma, Follicular	01/23	08/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	Active, not recruiting	3	650	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib	Loxo Oncology, Inc., Eli Lilly and Company	Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma	06/25	01/28
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma	Terminated	2	37	Europe	Copanlisib, ALIQOPA	Fondazione Italiana Linfomi - ETS	Diffuse Large B-cell Lymphoma	12/24	12/24
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression	Active, not recruiting	2	82	Europe, US, RoW	brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone	Seagen, a wholly owned subsidiary of Pfizer	Peripheral T-cell Lymphoma	05/24	12/25
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas	Recruiting	1	140	Europe, Canada, US, RoW	IKS03	Iksuda Therapeutics Ltd.	B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma	09/25	09/27
FISM_registry, NCT02808858: Italian Network MDS Registry	Recruiting	N/A	10000	Europe		Fondazione Italiana Sindromi Mielodisplastiche-ETS	Myelodysplastic-Myeloproliferative Diseases	06/16	05/32
PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role	Recruiting	N/A	350	Europe		International Extranodal Lymphoma Study Group (IELSG)	Marginal Zone Lymphoma	12/25	12/25
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by	Recruiting	N/A	12500	Europe		Gruppo Italiano Malattie EMatologiche dell'Adulto	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type	10/26	10/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vitolo, Umberto
FIL FLAZ12, NCT01827605 / 2012-000251-14: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)	Active, not recruiting	3	159	Europe	ZEVALIN, RIT, BEAM, ASCT	Fondazione Italiana Linfomi - ETS	Relapsed Follicular Lymphoma	10/19	01/24
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL	Recruiting	3	870	Europe	R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)	Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum	Mantle Cell Lymphoma	05/21	05/26
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients	Active, not recruiting	3	128	Europe	R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)	Fondazione Italiana Linfomi - ETS	Lymphoma, Follicular	01/23	08/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	Active, not recruiting	3	650	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib	Loxo Oncology, Inc., Eli Lilly and Company	Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma	06/25	01/28
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma	Terminated	2	37	Europe	Copanlisib, ALIQOPA	Fondazione Italiana Linfomi - ETS	Diffuse Large B-cell Lymphoma	12/24	12/24
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression	Active, not recruiting	2	82	Europe, US, RoW	brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone	Seagen, a wholly owned subsidiary of Pfizer	Peripheral T-cell Lymphoma	05/24	12/25
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas	Recruiting	1	140	Europe, Canada, US, RoW	IKS03	Iksuda Therapeutics Ltd.	B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma	09/25	09/27
FISM_registry, NCT02808858: Italian Network MDS Registry	Recruiting	N/A	10000	Europe		Fondazione Italiana Sindromi Mielodisplastiche-ETS	Myelodysplastic-Myeloproliferative Diseases	06/16	05/32
PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role	Recruiting	N/A	350	Europe		International Extranodal Lymphoma Study Group (IELSG)	Marginal Zone Lymphoma	12/25	12/25
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by	Recruiting	N/A	12500	Europe		Gruppo Italiano Malattie EMatologiche dell'Adulto	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type	10/26	10/26